Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Be’er Ya’akov Mental Health Center, Israel
1 July, 2009
A clinical trial in Chronic Obstructive Pulmonary Disease Patients with an Addiction to Smoking, has begun at the Mental Health Center in Be’er Ya’akov, Israel.
The study aim is to assess the efficacy of Brainsway® Deep TMS device in inducing smoking cessation in chronic obstructive pulmonary disease patients. Between 90 and 120 patients are expected to participate in the trial. The trial will be a blinded placebo-controlled study.